Discontinuing Clozapine and Transitioning to Alternative Treatments

Introduction to Clozapine Discontinuation

The American Psychiatric Association recommends against discontinuing clozapine in patients with treatment-resistant schizophrenia, as it is the only evidence-based treatment for this condition, and switching to less effective alternatives is clinically inappropriate 1
Clozapine is irreplaceable for treatment-resistant schizophrenia, with no other antipsychotic, including olanzapine or risperidone, demonstrating equivalent efficacy in this population 1

A high clozapine level without symptoms suggests metabolic tolerance rather than toxicity, with therapeutic levels typically ranging from 350-550 ng/mL, although some patients may require and tolerate higher concentrations 1, 2
The combination of olanzapine plus risperidone has no evidence base and represents antipsychotic polypharmacy without clozapine's unique efficacy 1

Verify the reason for discontinuation is medically justified, such as agranulocytosis, myocarditis, or severe metabolic decompensation, as patient preference alone is insufficient given clozapine's unique efficacy 1
Consider dose reduction to achieve levels of 350-550 ng/mL before considering full discontinuation, as this maintains clozapine's unique efficacy while addressing the elevated level 1, 2
If discontinuation is necessary, a gradual taper over 3-4 weeks minimum is recommended to reduce withdrawal symptoms and relapse risk, although specific taper schedules may vary 2, 3, 4

Risperidone should not be added simultaneously with olanzapine, as this creates antipsychotic polypharmacy without evidence of benefit, and olanzapine monotherapy at 10-20mg daily for 4 weeks should be tried first 1
If olanzapine monotherapy fails to control symptoms, consider switching to risperidone rather than combining, with risperidone dosing starting at 2mg daily and potentially increasing to 4-6mg daily 1, 3

If augmentation is needed, add aripiprazole 5-15mg daily, as this is an evidence-based clozapine augmentation strategy, rather than switching to less effective alternatives 4
Consider concurrent metformin to attenuate weight gain associated with olanzapine, as olanzapine has a high metabolic risk 1